Asia-Pacific Cancer Vaccines Market - Segmented by Type, Technology, End User and Geography 2017 - 2022

  • ID: 4388360
  • Report
  • Region: Asia Pacific
  • 75 pages
  • Mordor Intelligence
1 of 4
Cancer vaccines are biological preparations that stimulate or strengthen a person's immune system against cancer. Cancer vaccines are usually administered intravenously. They can be used for both adults and children. The vaccines can be broadly classified into prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of the disease. Analysts forecast the Asia-Pacific cancer vaccines market to grow at a CAGR of 12-20% over the period (2017 - 2022). The Asia-Pacific market is currently estimated to be valued at USD 209 million as per 2015.

The market for cancer vaccines is much smaller than other cancer therapeutic categories. The size of the market can be attributed to the nascent stages of industry life cycle and the late introduction of the vaccines in the market. To tap this market, many companies from Asia-Pacific are actively investing in cancer vaccine development. The market penetration is expected to increase with the increase in competition among the various pharmaceutical companies to obtain a larger portion of this market.

The Asia-Pacific cancer vaccines market is segmented based on:

Technology

Subunit Vaccines

Live Attenuated Vaccines

Conjugate Vaccines

Inactivated Vaccines

Recombinant Vector Vaccines

Toxoid Vaccines

Synthetic Vaccines

Dendritic Cell Vaccines

Type

Preventive Vaccines

Therapeutic Vaccines

Disease Indication

Cervical cancer

Others

End user

Pediatrics

Adults

Geography

China

India

Japan

Singapore

According to the World Health Organization, 14-million incidences of cancer and 8.2-million cancer deaths were recorded in 2012. Lung, prostate, colorectal, cervical, and breast cancers remain the most common forms of cancer. Thus, there is a rise in demand for vaccines to prevent and treat cancers.

Asia is poised to grow at the highest CAGR during the forecast period, owing to governmental initiatives, rising focus of major players on the Indian vaccine technology market, and increasing immunization initiatives by organizations such as World Health Organization and GAVI in these regions.

Some of the key participants in the industry include Prima BioMed, GlaxoSmithKline, Sanofi S.A, Merck, Aduro BioTech, AstraZeneca plc, OXFORD BIOMEDICA etc.

Drivers:

Increasing cancer cases

Technological developments

Drug innovations with regard to the cancer

Government initiatives

Rise in aging populace

Advanced health care services

Upsurge in awareness about cancer and their available therapies in the market

Increasing health care expenditure

Restraints:

Cold chain, or temperature-controlled supply chain, management

Low accessibility to vaccines in remote areas

Stringent regulatory procedures

SPECIALITIES OF THIS REPORT

The report will be useful in gaining an exhaustive understanding of the regional market. It will also be of assistance in providing a comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.

The report will be an ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.

The report contains wide range of information about the leading market players and the major strategies adopted by them.

WHAT THE REPORT OFFERS

Market definition along with identification of key drivers and restraints for the market.

Market analysis with region specific assessments and competition analysis on a global andregional scale.

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.

Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. Executive Summary
2. Research Methodology
3. Introduction
3.1 Report Description
3.2 Markets Covered
4. Market Overview
4.1 Market Definition
4.2 Market Drivers
4.2.1 Increased Prevalence of Cancers
4.2.2 Rising Government and Non-Government Funding for Vaccine Development
4.2.3 Increasing Investments By Companies
4.2.4 Technological Advancements
4.3 Market Restraints
4.3.1 Cold Chain Management
4.3.2 Huge Capital Investments
4.3.3 Stringent Regulatory Procedures
4.4 Market Opportunitites
4.5 Market Threats
5. Porters Five Force Analysis
5.1 Bargaining Power of suppliers
5.2 Bargaining power of buyers
5.3 Degree of competition
5.4 Threat of substitution
5.5 Threat of new entrants
6. Market Segmentation
6.1 By Technology
6.1.1 Subunit Vaccines
6.1.2 Live Attenuated Vaccines
6.1.3 Conjugate Vaccines
6.1.4 Inactivated Vaccines
6.1.5 Recombinant Vector Vaccines
6.1.6 Toxoid Vaccines
6.1.7 Synthetic Vaccines
6.1.8 Dendritic Cell Vaccines
6.2 By Type
6.2.1 Preventive Vaccines
6.2.2 Therapeutic Vaccines
6.3 By Disease Indication
6.3.1 Cervical cancer
6.3.2 Others
6.4 By End User
6.4.1 Pediatrics
6.4.2 Adults
6.5 By Geography
6.5.1 China
6.5.2 India
6.5.3 Japan
6.5.4 Australia
6.5.5 Singapore
7. Competitive Landscape
7.1 Mergers & Acquisitions
7.2 Agreements, Collaborations & Partnerships
7.3 New Product Launches
7.4 Recommendations to new market players
7.5 Value Chain Analysis
8. Company Profiles
8.1 AstraZeneca plc
8.2 Aduro BioTech
8.3 Cytos
8.4 Galena Biopharma
8.5 Juvaris Biotherapeutics
8.6 MedImmune
8.7 Oxford BioMedica
8.8 Prima BioMed
8.9 GlaxoSmithKline
8.10 Sanofi
8.11 Merk&co
8.12 Ubivac
8.13 Vaccinogen
9. Appendix
9.1 Abbrevations
9.2 Sources
9.3 Bibliography
9.4 Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll